LINTHICUM, Md., Aug. 26, 2005 (PRIMEZONE) -- Dialysis Corporation of America (Nasdaq:DCAI) announced the development of a new dialysis center in Calhoun, Georgia, marking the company's seventh center in that state. The company also opened its new Baltimore, Maryland facility that, as previously announced, began construction earlier this year.
President & CEO Stephen Everett commented, "We look forward to expanding our presence in Georgia and anticipate our new Calhoun location to be another success for our company. Additionally, we have completed the construction of our Baltimore, Maryland facility, passed all required inspections, and have opened the facility for patient care. This center is our first in the greater Baltimore area and our third in the state."
The new Calhoun center will begin construction shortly and be designed to offer state-of-the-art equipment and technology, with patient comfort in mind, and include 15 treatment stations.
Dialysis Corporation of America owns and operates freestanding kidney hemodialysis centers located in Georgia, Maryland, New Jersey, Ohio, Pennsylvania, South Carolina, and Virginia, and provides in-hospital dialysis services on a contract basis to certain hospitals located in the those states. The company provides patients with their choice of a full range of quality in-center, acute or at-home hemodialysis services.
This release contains forward-looking statements that are subject to risks and uncertainties that could affect the business and prospects of the company and cause actual results and plans to differ materially from those anticipated. Those factors include, but are not limited to, certain delays beyond the company's control with respect to future business events, the highly competitive environment in the establishment and operation of dialysis centers, the ability to develop or acquire additional dialysis facilities, whether patient bases of the company's facilities can expand to provide profitability, regulation of dialysis operations, government rate determination for Medicare reimbursement, and other risks detailed in the company's filings with the Securities and Exchange Commission, particularly as described in the company's proxy statement/prospectus relating to the merger of its parent, Medicore, Inc., with the company, and in its annual report on Form 10-K/A1 for the fiscal year ended December 31, 2004.
Other Dialysis Corporation of America press releases, corporate profile, corporate governance materials, quarterly and current reports, and other filings with the Securities and Exchange Commission are available on Dialysis Corporation of America's Internet home page: http://www.dialysiscorporation.com.